LOWFederal Register

Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration

Published Jul 24, 2026Source: Federal RegisterView original

Summary

This is a licensing opportunity notice from the National Eye Institute seeking co-development partners for a PEDF peptide-based therapy for inherited retinal diseases. It is an informational technology transfer announcement rather than a regulatory change, and does not impose restrictions or new rules on peptide vendors or researchers.

AI Analysis

Key Changes

•NEI is making a government-owned invention (PEDF peptides for retinal degeneration) available for license
•Opportunity for research co-development partnerships on AAV2-based delivery or eyedrop formulation
•Gene-agnostic therapeutic approach targeting inherited retinal diseases

Affected Compound

Pigment Epithelium-Derived Factor (PEDF) peptide

Action Required

Peptide research companies or biotech firms interested in commercializing PEDF peptide therapeutics may contact NEI to pursue licensing or co-development partnerships; no compliance action required.

Effective Date

Jul 24, 2026

Full Document Text

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium- Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.

Alert created: Jul 24, 2026, 5:31 AM